HALEOSLABS · NSE
HALEOS LABS LIMITED
₹1,487.6
-0.67% (-₹10)
Prev. close
₹1,497.6
Volume
2,181
Delivery %
82.6%
As of
21 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About HALEOS LABS LIMITED
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also export its products. The company was formerly known as SMS Lifesciences India Limited and changed its name to Haleos Labs Limited in August 2025. Haleos Labs Limited was founded in 1990 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Talluri Veera Venkata Satyanarayana Murthy
Headquarters
Hyderabad
Employees
611
Website
haleoslabs.comExchange
View on NSE ↗Key stats
Market cap
₹453.49 Cr
P/E ratio (TTM)
28.7
Dividend yield
0.10%
EPS (TTM)
₹52.21
Beta (1Y · daily vs NIFTY 50)
0.57
Beta (5Y · monthly vs NIFTY 50)
0.73
Shares float
7.56 L
EPS · quarter ended Jun 2026
₹8.75
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹265.59 Cr | ₹349.74 Cr | ₹315.56 Cr | ₹305.96 Cr | ₹344.72 Cr | ₹333.79 Cr | |
| EBITDA | ₹31.96 Cr | ₹48.91 Cr | ₹34.18 Cr | ₹34.94 Cr | ₹49.90 Cr | ₹47.11 Cr |
| ₹13.56 Cr | ₹25.32 Cr | ₹11.46 Cr | ₹9.09 Cr | ₹20.11 Cr | ₹17.31 Cr | |
| Diluted EPS | ₹44.84 | ₹83.68 | ₹37.92 | ₹30.08 | ₹66.51 | ₹57.26 |
EBITDA for Mar 2022 could not be independently verified against the company's own annual report: this page shows ₹48.91 Cr while the annual report gives ₹36.22 Cr (25.9% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹27.67 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹302.00 Cr | ₹357.00 Cr | ₹395.00 Cr | ₹391.00 Cr | ₹390.00 Cr | ₹454.00 Cr | |
| — | ₹79.60 Cr | ₹100.49 Cr | ₹100.72 Cr | ₹86.41 Cr | ₹110.54 Cr | |
| Stockholders' equity | ₹129.00 Cr | ₹152.00 Cr | ₹169.00 Cr | ₹177.00 Cr | ₹197.00 Cr | ₹214.00 Cr |
Total debt, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹35.00 Cr | ₹-11.00 Cr | ₹15.00 Cr | ₹24.00 Cr | ₹34.00 Cr | ₹37.00 Cr | |
| Investing cash flow | ₹-26.23 Cr | ₹-7.14 Cr | ₹-31.29 Cr | ₹-18.45 Cr | ₹-15.00 Cr | ₹-57.90 Cr |
| ₹-2.55 Cr | ₹10.83 Cr | ₹16.89 Cr | ₹-6.56 Cr | ₹-19.12 Cr | ₹21.38 Cr | |
| Capital expenditure | ₹-36.00 Cr | ₹-51.00 Cr | ₹-49.00 Cr | ₹-21.00 Cr | ₹-15.00 Cr | ₹-58.00 Cr |
| End cash position | ₹8.54 Cr | ₹98.60 L | ₹1.28 Cr | ₹56.95 L | ₹50.29 L | ₹1.21 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Mar 20 | Sep 21 | Dec 21 | Mar 22 | Jun 22 | Sep 22 | Dec 22–Sep 23(4Q) | Dec 23 | Mar 24 | Jun 24–Sep 25(6Q) | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.00% | 67.74% | 67.69% | 68.96% | 69.85% | 69.86% | 70.32% | 70.68% | 71.19% | 71.41% | 71.80% | 72.11% |
| Public | 32.00% | 32.26% | 32.31% | 31.04% | 30.15% | 30.14% | 29.68% | 29.32% | 28.81% | 28.59% | 28.20% | 27.89% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,846.4 | 37.1 | 5.37 | 13.7% | 0.06 | +11.9% | +12.3% |
| Divi's Laboratories Limited | ₹2.49 L Cr | ₹9,410.5 | 84.7 | 14.85 | 15.3% | 0.00 | +12.3% | +51.8% |
| Torrent Pharmaceuticals Limited | ₹1.84 L Cr | ₹4,970 | 77.5 | 21.95 | 25.8% | 1.79 | +21.5% | +36.9% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,835.5 | 61.5 | 13.52 | 20.5% | 0.90 | +15.7% | +14.2% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹691.45 | 179.0 | 13.55 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.16 L Cr | ₹1,161 | 25.8 | 4.27 | 18.6% | 0.46 | +18.4% | +11.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,384.1 | 33.2 | 3.25 | 11.3% | 0.02 | +2.1% | -10.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,006.5 | 99.3 | 20.57 | 16.8% | 0.48 | +22.0% | +122.0% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,066.6 | 70.4 | 9.50 | 13.4% | 0.32 | +19.0% | -8.0% |
| Manipal Health Enterprises Limited | ₹99,047.90 Cr | ₹746.1 | 152.1 | 11.75 | 7.8% | 1.53 | +18.0% | — |
| Dr. Reddy's Laboratories Limited | ₹98,709.15 Cr | ₹1,198.3 | 29.8 | 2.62 | 11.4% | 0.21 | +3.2% | -9.3% |
| HALEOS LABS LIMITED | ₹453.49 Cr | ₹1,487.6 | 28.7 | 2.12 | 8.1% | 0.52 | -6.3% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.